Literature DB >> 17660718

Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004-2006.

Anne McNicholas1, Yvonne Galloway, Paul Stehr-Green, Stewart Reid, Sarah Radke, Kerry Sexton, Charlotte Kieft, Claire Macdonald, Jocelyn Neutze, Ross Drake, Dorothy Isaac, Mary O'Donnell, Michael Tatley, Philipp Oster, Jane O'Hallahan.   

Abstract

New Zealand introduced a new outer membrane vesicle vaccine in 2004 to combat an epidemic of group B meningococcal disease. An Independent Safety Monitoring Board oversaw intensive safety monitoring, which included hospital surveillance, health professional reporting (passive and active) and mortality monitoring. With over three million doses administered to individuals aged under 20 years, the monitoring results provide consistent evidence supporting the vaccine's safety.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17660718     DOI： 10.4161/hv.3.5.4458

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN： 1554-8600


  12 in total

1.  IMPACT after 17 years: Lessons learned about successful networking.

Authors: 
Journal:  Paediatr Child Health       Date:  2009-01       Impact factor: 2.253

2.  IMPACT after 17 years: Lessons learned about successful networking.

Authors: 
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

3.  Background rates of disease in Latin American children from a rotavirus vaccine study.

Authors:  Marc Baay; Kaatje Bollaerts; Claudio Struchiner; Thomas Verstraeten
Journal:  Hum Vaccin Immunother       Date:  2017-04-25       Impact factor: 3.452

4.  Cost-utility analysis of a nationwide vaccination programme against serogroup B meningococcal disease in Israel.

Authors:  Gary M Ginsberg; Colin Block; Chen Stein-Zamir
Journal:  Int J Public Health       Date:  2016-04-22       Impact factor: 3.380

5.  Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines.

Authors:  Steven Black; Juhani Eskola; Claire-Anne Siegrist; Neal Halsey; Noni MacDonald; Barbara Law; Elizabeth Miller; Nick Andrews; Julia Stowe; Daniel Salmon; Kirsten Vannice; Hector S Izurieta; Aysha Akhtar; Mike Gold; Gabriel Oselka; Patrick Zuber; Dina Pfeifer; Claudia Vellozzi
Journal:  Lancet       Date:  2009-10-31       Impact factor: 79.321

6.  Cost-effectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence.

Authors:  Koen B Pouwels; Eelko Hak; Arie van der Ende; Hannah Christensen; Germie P J M van den Dobbelsteen; Maarten J Postma
Journal:  Hum Vaccin Immunother       Date:  2013-02-13       Impact factor: 3.452

7.  Health and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian routine infant immunisation programme.

Authors:  Marcello Tirani; Michela Meregaglia; Alessia Melegaro
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

Review 8.  Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future.

Authors:  Johan Holst; Philipp Oster; Richard Arnold; Michael V Tatley; Lisbeth M Næss; Ingeborg S Aaberge; Yvonne Galloway; Anne McNicholas; Jane O'Hallahan; Einar Rosenqvist; Steven Black
Journal:  Hum Vaccin Immunother       Date:  2013-03-07       Impact factor: 3.452

9.  Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact.

Authors:  Hannah Christensen; Matthew Hickman; W John Edmunds; Caroline L Trotter
Journal:  Vaccine       Date:  2013-04-06       Impact factor: 3.641

10.  Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study.

Authors:  Hannah Christensen; Caroline L Trotter; Matthew Hickman; W John Edmunds
Journal:  BMJ       Date:  2014-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.